ABSTRACT
INTRODUCTION
Ulcerative colitis (UC), along with Crohn's disease (CD) and inflammatory bowel disease undetermined type (IBDU) make up the spectrum of inflammatory bowel diseases (IBD). IBD affects thousands of children worldwide [1] [2] [3] [4] . The highest incidence occurs in developed industrialized countries, with 2-7 children per 100,000 becoming affected each year in the USA [3, 5] . IBD is a destructive chronic inflammatory condition of the gastrointestinal (GI) tract, and thus far the etiology remains poorly understood, although numerous studies point to a combination of genetic, environmental, and host factors.
Current hypotheses of the pathogenesis of IBD suggest that pathogenic or normal enteric flora provide antigenic stimulation leading to a dysregulated immune response in genetically susceptible individuals with multiple potential environmental predisposing factors causing tissue damage and disease pathology [6] [7] [8] [9] . In this review, the authors will discuss current therapies in pediatric UC, with a focus on the indications for and the use of infliximab in treating children with moderately-to-severely active UC.
PATHOPHYSIOLOGY OF UC
While much of the etiology of IBD remains undetermined, the altered balance between enteric flora and the intestinal immune response in genetically susceptible individuals has been well described [10, 11] . Luminal antigens interact with the mucosa normally, yet with increased permeability one sees triggering of multiple inflammatory pathways, including the innate and adaptive immune systems [12] . In UC, in response to bacterial lipopolysaccharides, the T helper 2 (Th2) response produces cytokines, interleukin (IL)-5, and IL-13, as well as other proinflammatory cytokines, which induce macrophages, monocytes, neutrophils, T cells, and natural killer (NK) cells to secrete tumor necrosis factora (TNF-a), IL-1, and IL-6 [10, 11, 13] . TNF-a activates leukocytes, induces acute phase reactants, and inhibits apoptosis of inflammatory cells, and can be found in significant amounts in the mucosa of patients with active UC [14] . Leukocytes migrate into the mucosa, and release proteases, nitric oxide, prostaglandins, free oxygen radicals, endopeptidases, and chemokines which both directly damage tissue and further amplify the inflammatory process [11] . Understanding the etiology of UC has guided the development of treatment for the disease and the approach to this illness.
The complex dysregulated immune response along with severe inflammation lead to the key feature of UC: diffuse superficial mucosal inflammation extending proximally from the rectum to varying locations [10] . The affected area of the colon is variable and can affect
anywhere from the distal sigmoid alone, to pancolitis. As compared with adults, the pediatric UC population tend to present with more extensive colonic involvement and more commonly present with moderate-to-severe disease activity [15] . Pediatric UC patients commonly present with hematochezia, diarrhea, and abdominal pain. Diagnostic evaluation consists of a detailed history, physical exam, laboratory data, small bowel imaging, upper GI endoscopy, and colonoscopy. While pediatric UC is limited to colonic inflammation, upper endoscopy is key in evaluating for signs of CD. Histologic findings are essential in confirming the diagnosis of UC, and include colonic mucosal inflammation, crypt distortion, crypt microabscesses, and goblet cell depletion [16] .
Role of TNF-a in UC
TNF-a, produced by activated macrophages and T lymphocytes, is a key proinflammatory cytokine in IBD. TNF-a has multiple actions, including: (5) inhibiting regulatory macrophages which have suppressive effects on the immune system, including inhibiting the proliferation of activated T cells [17] [18] [19] . TNF-a has been found in increased amounts in the mucosa of patients with UC [14] .
Clinical Scoring of UC
Defining the severity of disease activity is imperative in determining a treatment approach. The moderate-to-severe phenotype is a common presentation in children, with [80% of children presenting with macroscopic inflammation beyond the splenic flexure, as compared to less than half of adults with disease limited to the rectosigmoid [20] . While there is a paucity of data on the frequency of severe UC exacerbation in children, reported data on the prevalence of severe UC at diagnosis varies from 15 to 57%. In pediatrics, use of the validated Pediatric Ulcerative Colitis Activity Index (PUCAI) based on clinical symptom reporting, is useful in stratifying disease severity, in which a PUCAI score of at least 65 was highly associated with physician global assessment of severe disease (sensitivity 92%, specificity 94%) [21, 22] . Prospective data has supported the use of PUCAI scoring in helping gauge treatment decisions. Using this system, approximately one-third of children with moderate-to-severe PUCAI scores requiring hospital admission and intravenous (IV) steroids will fail IV steroids, and go on to require more intensive therapies.
Of those children who responded to IV steroids, most responded within 6 days of therapy [23] . there is significantly less data to support the use of these therapies in children as compared to adults. There are strong data to support the use of 5-ASA as initial therapy in mild-tomoderate UC [27] . The mechanism of action of 5-ASA remains unclear, although the primary effect is considered to be an anti-inflammatory effect directly on the mucosa, and as such is available in multiple formulations, including oral and rectal preparations (for more direct administration of disease limited to proctitis or distal left-sided disease) [28, 29] . While there have been minimal data on inducing and maintaining remission in pediatric UC, the data are strong in adult UC for both inducing remission, with number needed to treat estimated at 5, with 40% of patients achieving disease remission versus 20% with placebo, as well as preventing relapse, with 40% of patients on 5-ASA therapies relapsing versus 63% relapsing on placebo [25, 30] .
Corticosteroid therapy has been a mainstay of treatment of UC and symptomatic management, although it has been well established that corticosteroids do not promote mucosal healing [31, 32] . However, up to a third of children with UC will require corticosteroids to achieve disease remission at the time of diagnosis, one-fifth will become steroid dependent, and an additional one-third will require surgery [33] . In patients with no or partial response to oral, rectal, or topical corticosteroids, treatment often escalates to inpatient admission and IV steroid therapy [28, 33, 34] . As noted above, in those who fail IV steroid therapy, second-line therapy must be considered. In adults, both IV cyclosporine and oral tacrolimus have also been shown to be effective at inducing remission in IV steroid failure [35] [36] [37] [38] . The use of IV cyclosporine has not been as successful in small pediatric cohort studies, which demonstrated short benefit with the use of cyclosporine with successful delay of colectomy of 81% of patients in the acute period, but only 39% avoided colectomy at long-term follow-up; and thus with its significant side effect profile including nephrotoxicity, it is not indicated in maintaining remission [24, 39] .
The role of immunomodulators, including 6-MP and its prodrug azathioprine, has been indicated in maintaining remission of disease. In a prospective cohort study, at 12-month followup of 133 patients receiving a thiopurine immunomodulator, 49% had steroid-free inactive disease without the need for escalating therapies, and an additional 10% had steroid-free mild disease [40] . The use of these therapies must be closely monitored, including a thiopurine methyltransferase (TPMT) enzyme level, which metabolizes 6-MP to its active metabolites [42] . Elective surgery should be considered in those with refractory disease, signs of colonic dysplasia or rectal cancer, or those who chose to decline biologic therapy [43] . The most widely accepted surgical technique includes a total proctocolectomy with ileal j-pouch anal anastomosis, generally staged with a temporizing diverting ileostomy.
Surgery is not without complications, including increased risks of pouchitis, increased stooling frequency, incontinence, reduced fertility, need for surgical revision or reoperation, and pouch failure. Reported failure rates in adults range from 6.8 to 8.5% at 36-60 months post colectomy [44] . Although surgical intervention can be potentially curative for UC, achieving sustained clinical remission while preserving the colon is the optimal successful outcome.
Anti-TNF-a antibody agents offer an opportunity to avoid colectomy.
INFLIXIMAB
Infliximab is a chimeric murine-human monoclonal immunoglobulin G1 antibody composed of a murine variable region linked to a human constant region, and is produced by cell culture using Chinese hamster ovary cells [45] [46] [47] . Infliximab is administered IV and remains in the extracellular fluid, binding to human TNF-a with high affinity and inducing apoptosis of T cells and monocytes [48] . It has an approximate half-life of 10 days and with a single 5 mg/kg dose, levels are no longer detectable (\0.1 lg/mL) by 12 weeks postinfusion. The effect on inflammatory cytokines can be rapid, with normalization of IL-6 levels within 2 weeks of therapy [46, 49] . Overall, the data have been supportive for the use of infliximab in the pediatric UC population for improving clinical symptoms and for some, achieving disease remission, with evidence of endoscopic healing [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] . Seminal studies addressing the use of infliximab for the treatment of UC are summarized in Table 1 [ [56] [57] [58] [59] [60] [61] [62] [63] [64] . This was initially found as part of treating a generalized cohort of pediatric patients with IBD [55] . Cucchiara et al. [61] had a larger cohort of patients maintained on infliximab beyond the initial induction phase of 6-8 weeks. In their cohort of 22 patients, 12 patients acutely responded to infliximab, eight of whom went on to receive infliximab routinely every 8 weeks, while the remaining four went on to receive azathioprine alone. Follow-up at 54 weeks found that both groups remained in clinical remission [61] . These findings warrant further examination for the clinical utility in infliximab maintaining remission, for which data is lacking in both adult and pediatric populations [30] .
Hyams et al. [63] corroborated the above data with data from the Pediatric Inflammatory
Bowel Disease Collaborative Research Group
Registry, a multicenter consortium of 21 IBD centers in the United States and Canada. In their cohort of 52 patients, a majority of which had moderately-to-severely active UC (84%), a significant proportion responded to infliximab (36% with inactive disease, 19% with mild disease after treatment), although a portion of those patients remained on corticosteroids; as to whether these were being tapered or maintained for disease activity is unknown.
On longitudinal follow-up, those who remained with inactive and mild disease decreased to 21 and 11%, respectively, with a cumulative colectomy rate of 16. It is difficult to extrapolate whether this loss of sustained response was secondary to infliximab, as a majority of patients remained on infliximab therapies for varying lengths of time [63] . Longitudinal use of infliximab was more clearly studied in patients with a response to acute infliximab therapy (44 of 60 patients) who were randomized to receive infliximab every 8 or 12 weeks. Follow-up at 54 weeks indicated that there were more subjects in remission in the cohort who received infliximab every 8 weeks (8 of 22 patients) versus 12-week dosing (4 of 22 patients), with an overall remission rate of 28.6% [64] . These data were supported by Turner et al., who noted that in a cohort of 33 patients who received infliximab, at 1-year follow-up, 52% of those who initially responded to infliximab remained in remission [23] .
Taken together, the available pediatric However, when there is inadequate response, especially in the setting of sub therapeutic infliximab trough levels, the dosage may be increased (up to 10 mg/kg) or the dosing interval may be decreased.
Immunogenicity of Infliximab
A well-described phenomenon in the use of monoclonal antibody therapy is the antigenic potential of the antibody to elicit a host immune response against the treatment, known as immunogenicity. In the case of infliximab, this potential for developing human anti chimeric antibodies (HACA) and thereby having accelerated degradation of infliximab is a potential explanation for those who develop a loss of therapeutic response, lack of response, and infusion reactions [68] [69] [70] . [72] . In a small single center study from Finland (n = 23), adverse reaction rates were reported as 26%, including abscess at infusion site, anaphylaxis, urticaria, dizziness, and nausea, chest pain, and severe sepsis with multifocal leukoencephalopathy in a 16-year-old male which resolved within 6 months of discontinuation of therapy [73] . However, in the aforementioned studies, only two patients were reported as having to discontinue therapy, a minority requiring treatment with acetaminophen and diphenhydramine and a minority with transient symptoms of flushing, dizziness, pruritis, and tachycardia which resolved spontaneously [56] [57] [58] [59] [60] . Two reported patients required antibiotics; one received oral therapy for an upper respiratory infection, the other required IV antibiotic therapy for a local cellulitis at the injection site [65] .
Finally, concerns have been raised regarding increased risks of malignancies in children on anti-TNF-a therapy, including leukemia, Hodgkin's and non-Hodgkin's lymphoma, hepatosplenic T cell lymphoma (HSTCL), melanoma, and solid organ tumors, with 48 cases reported from a database search of the FDA's Adverse Event Reporting System [74] .
Upon further investigation of risk factors associated with developing HSTCL, it was mainly associated with young males who had been exposed to both anti-TNF-a antibody therapy and thiopurine immunomodulators [75] . The authors did not find any association with HSTCL in patients who had received anti-TNF-a antibody therapy alone, implying that TNF-a blockade alone may be necessary but not sufficient to lead to malignancy. At this time, there does appear to be an increased risk of malignancy associated with anti-TNF-a therapy but the low incidence reported does not preclude the use of this therapy for treating IBD; however, the body of data continues to grow.
Based on adult and pediatric data, while the use of infliximab must be monitored carefully for risks of infusion reactions or anaphylaxis and possible infection, overall it appears to be a safe therapy for use in the pediatric population.
OTHER ANTI-TNF-A AGENTS
There are currently multiple other anti-TNF-a agents on the market for the treatment of CD.
Two of these include adalimumab, a fully human monoclonal antibody against TNF-a and certolizumab pegol, a pegylated Fab fragment of a humanized anti-TNF-a monoclonal antibody.
While there is no current randomized, controlled pediatric trial in the treatment of UC with either biologic therapy, there are adult studies on the use of adalimumab, although it is currently not FDA approved for this indication. Sandborn et al.
[76] evaluated the efficacy of adalimumab in adult patients with UC. In a controlled and double-blinded study they found adalimumab to be safe and more effective than placebo for the induction and maintenance of remission in patients with moderate-to-severe UC refractory to conventional therapy. There is one small, retrospective study of ten pediatric patients with IBD treated with adalimumab due to a lack or loss of response to infliximab. In this study, three patients with UC achieved improvement in the short term [77] . However, one of these patients later failed adalimumab treatment and required colectomy. This study included a very small number of UC subjects and larger studies are required to determine the efficacy of adalimumab in pediatric UC. 
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